Relx (LON:REL) Price Target Raised to GBX 2,250
Relx (LON:REL) had its price objective increased by JPMorgan Chase & Co. from GBX 1,950 ($25.65) to GBX 2,250 ($29.60) in a report issued on Friday, Stock Target Advisor reports. The firm currently has an overweight rating on the stock.
REL has been the topic of a number of other research reports. Goldman Sachs Group upped their price target on shares of Relx from GBX 2,378 ($31.28) to GBX 2,408 ($31.68) and gave the company a buy rating in a research note on Monday, January 20th. HSBC reiterated a buy rating on shares of Relx in a research note on Monday, January 13th. Berenberg Bank lowered shares of Relx to a hold rating and decreased their price target for the company from GBX 2,120 ($27.89) to GBX 2,100 ($27.62) in a research note on Friday. UBS Group reiterated a sell rating and issued a GBX 1,825 ($24.01) price target (up previously from GBX 1,790 ($23.55)) on shares of Relx in a research note on Friday. Finally, Barclays upped their price target on shares of Relx from GBX 2,090 ($27.49) to GBX 2,275 ($29.93) and gave the company an overweight rating in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. Relx currently has an average rating of Buy and an average price target of GBX 2,043 ($26.87).
Shares of REL opened at GBX 2,067 ($27.19) on Friday. Relx has a 52 week low of GBX 1,597 ($21.01) and a 52 week high of GBX 2,100 ($27.62). The firm has a market cap of $40.09 billion and a P/E ratio of 26.81. The firm’s 50-day simple moving average is GBX 1,998.16 and its 200 day simple moving average is GBX 1,908.57. The company has a debt-to-equity ratio of 308.02, a quick ratio of 0.40 and a current ratio of 0.45.
Relx Company Profile
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Further Reading: Guidelines for Successful Channel Trading
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.